Citigroup
CHRS icon

Citigroup’s Coherus Oncology CHRS Stock Holding History

Citigroup’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,600
Closed -$14K – 7657
2018
Q4 		$14K Hold
1,600
– – ﹤0.01% 7030
2018
Q3 		$26K Sell
1,600
-3,200
-67% -$56.7K ﹤0.01% 6955
2018
Q2 		$67K Buy
4,800
+1,200
+33% +$17.2K ﹤0.01% 6047
2018
Q1 		$40K Buy
3,600
+1,000
+38% +$10.9K ﹤0.01% 6326
2017
Q4 		$23K Buy
2,600
+800
+44% +$8.56K ﹤0.01% 6658
2017
Q3 		$24K Sell
1,800
-5,700
-76% -$75.4K ﹤0.01% 6376
2017
Q2 		$108K Buy
7,500
+2,500
+50% +$48.1K ﹤0.01% 5290
2017
Q1 		$106K Buy
+5,000
New +$123K ﹤0.01% 5165

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Citigroup's CHRS Position: Q2 2026 in Review

Citigroup increased its Coherus Oncology (CHRS) stake by 23% in Q2 2026, buying an estimated $19.6K and bringing the position to 64,342 shares worth $90.1K. The position accounts for ﹤0.01% of the portfolio, ranked #4739.

Citigroup first reported a position in CHRS in Q4 2014 and has held it in 47 quarters since. The position peaked at $12.7M in Q4 2021. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • Citigroup held 64,342 shares of Coherus Oncology worth $90.1K as of Q2 2026.
  • Citigroup bought 12,009 Coherus Oncology shares in Q2 2026, an estimated $19.6K.
  • Coherus Oncology made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4739 holding.
  • Citigroup first reported a position in Coherus Oncology in Q4 2014 and has held it in 47 quarters since.
  • Citigroup's Coherus Oncology position peaked at $12.7M in Q4 2021.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.